search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Business


Continued from page 61


18Von Krogh, G, Nonaka, K, Rechsteiner, L. Leadership in organizational knowledge creation: A review and framework. J Manag Stud 2012;49:240-77. 19 McEvily, B, Soda, G, Tortoriello, M. More Formally: Rediscovering the Missing Link between Formal Organization and Informal Social Structure. Acad Manag Ann 2014;8:299- 345. doi:10.1080/19416520. 2014.885252. 20 Ben-Menahem, SM, Von Krogh, G, Erden, Z, Schneider, A. Coordinating knowledge creation in multidisciplinary teams: Evidence from early- stage drug discovery. Academy of Management Journal. 2016 Aug;59(4):1308-38. 21 Martinez, JI, Jarillo, JC. The evolution of research on coordination mechanisms in multinational corporations. Journal of international business studies. 1989 Sep 1;20(3):489-514.


Dr Andreas Schneider co-leads the development of new drug delivery devices and digital business models at Ypsomed. Furthermore, he drives Ypsomed’s Science & Research Program with the objective to create new insights relevant to both industry and academia. He received his PhD in Innovation Management and Organisation Sciences from ETH Zürich.


Dr Guido Koch has been the COO at Topadur Pharma AG since February 2018. Before Guido was a Director in Global Discovery Chemistry (GDC) at Novartis Institutes for Biomedical Research (NIBR). During his career in NIBR, he has contributed to drug discovery and develop- ment in different phases starting from target iden- tification to early clinical trials in man. Guido was responsible for numerous external CRO collabora- tions and the GDC University relations network in Europe. Guido received his PhD in Chemistry from the University of Basel in 1996. After a post- doc at California Institute of Technology, he joined Novartis in 1997.


Dr Hans Widmer graduated in chemistry and obtained a PhD in structural biology from the ETH Zürich. After postdoctoral studies at UCSF he joined Sandoz in Basel, now Novartis. He assumed leadership positions in structure-based drug discovery, analytical sciences and knowledge management. In his current role he fosters scientif- ic interactions with academia.


Advanced Cell Diagnostics Agilent Technologies, Inc Biostrata Ltd


BioTek Instruments, Inc BMG Labtech GmbH


3,15 45 36 38 6


ADVERTISEMENT INDEX 8


Corning, Inc


Eurofins Discovery Services Horizon Discovery Group plc


OBC 22


Intellicyt Corporation a Sartorius Company 30 Labcyte, Inc


29


Mack Brooks Group Pacific Biosciences


Quanterix Corporation Select Biosciences Ltd Taconic Biosciences, Inc


11 35


IFC,21 IBC 4


62


Drug Discovery World Spring 2019


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64